Detalhe da pesquisa
1.
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.
Diabetes Obes Metab
; 25(9): 2626-2633, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344384
2.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Diabetes Obes Metab
; 25(12): 3453-3464, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712754
3.
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Diabetes Obes Metab
; 25(12): 3465-3477, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700627
4.
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.
Diabetes Obes Metab
; 24(4): 631-640, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34866291
5.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Diabetes Obes Metab
; 24(12): 2373-2382, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876235
6.
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
Qual Life Res
; 30(7): 2033-2043, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33886044
7.
Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Diabetes Obes Metab
; 22(3): 355-364, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31646727
8.
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Diabetes Obes Metab
; 21(11): 2570-2575, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31364266
9.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Diabetes Obes Metab
; 21(6): 1299-1304, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30714309
10.
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Diabetes Obes Metab
; 20(2): 409-418, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817231
11.
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Diabetes Obes Metab
; 20(8): 2023-2028, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603872
12.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
Diabetes Ther
; 12(7): 1929-1946, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097244
13.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Diabetes Ther
; 11(10): 2383-2399, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32880876
14.
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Lancet Neurol
; 19(7): 582-590, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562683
15.
Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
Patient Prefer Adherence
; 13: 561-576, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31114170
16.
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
Drugs R D
; 19(2): 213-225, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115873
17.
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol
; 6(5): 370-381, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483060
18.
Medication adherence and improved outcomes among patients with type 2 diabetes.
Am J Manag Care
; 23(7): e208-e214, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28850793
19.
Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database.
Patient Prefer Adherence
; 10: 1573-81, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27574406
20.
Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
Postgrad Med
; 128(8): 810-821, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27488824